Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | AGER | Q15109 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123336 | 1.00 | PTGES (0.47) | PTGESCTSDCXCR3AGERMTNR1A | |
| SCHEMBL1594516 | 0.82 | ALDH1A1 (0.52) | CXCR3KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5388097 | 0.82 | ALDH1A1 (0.52) | CXCR3KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3370759 | 0.80 | AGER (0.55) | CTSDAGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL862072 | 0.79 | AGER (0.47) | CTSDAGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL862071 | 0.79 | AGER (0.47) | CTSDAGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL5123798 | 0.78 | ACACB (0.51) | KMT2AMEN1 | |
| SCHEMBL7464376 | 0.78 | MGLL (0.49) | KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2400009 | 0.76 | OPRM1 (0.51) | CTSDAGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL2400012 | 0.76 | OPRM1 (0.51) | CTSDAGERMTNR1ACHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-7459432-B2 | Modification of feeding behavior | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080213803-A1 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH & SCIENCE UNIVERSITY | 2008-09-04 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1183245-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1183245-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6225330-B1 | Selective NPY (Y5) antagonists (tricyclics) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6218408-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6214853-B1 | DIETETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-10 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000064880-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | PTGES 1753/4885CTSD 2849/4885CXCR3 2659/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | PTGES 2059/4885CTSD 1771/4885CXCR3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.